A Comparative Study on Post-intervention Use of Tirofiban or Enoxaparin in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Jian-sheng WU
Wen-bin WEI
Fen-sheng WU
Xin-xia ZHANG
Shu-fen HU
Xue-song HU
摘要：Objectives To evaluate the efficacy and safety of post procedure use of platelet glycoprotein Ⅱ b/Ⅲ a receptor inhibitor (PGI) or low molecular weight heparin (LMWH) in patients with acute coronary syndrome (ACS) undergoing dual anti-platelet loading therapy and percutaneous coronary intervention (PCI). Methods This was a prospective randomized grouping controlled study in 174 patients with ACS received aspirin 300 mg plus clopidogrel 600mg loading before PCI. After procedure, patients were randomized to intravenous tirofiban for 12 -24 hours (tirofiban group) or subcutaneous enoxaparin for 5 days (enoxaparin group). Cardiac ischemic events, major bleeding complications, minor bleeding complications, thrombocytopenia, and vascular access complications in both groups were investigated. Results Cardiac ischemic events, major bleeding complications, minor bleeding complications, thrombocytopenia, and vascular access complications in tirofiban group were 8.0%, 3.4%, 6. 8%, 3.4%, and 3.4%, respectively. In enoxaparin group, aforementioned event rates were 7%, 2.3%, 6.0%, 2.3%, and 5.8%, respectively. No statistical significance was found between two groups. Conclusions In the setting of dual anti-platelet medication loading and PCI for the treatment of ACS, it is effective to use tirofiban or enoxaparin for aggressive post procedure antithrombotic therapy. It comes with a very low major bleeding complication rate. Use of GPI for 12 to 24 hours was comparable to use of LMWH for 5 days in efficacy and safety.
机标关键词：
分类号：R5(内科学)
论文发表日期：2009-07-02
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：5( 132-136 )
英文信息